肝硬化患者异位静脉曲张出血的管理与结局:系统综述与汇总分析
该系统综述汇总44项研究共458例肝硬化或门脉高压合并异位静脉曲张出血患者,评估现有疗法的安全性和有效性。结果显示内镜下硬化剂注射治疗直肠静脉曲张再出血率低于套扎(3.3% vs. 33.3%),TIPS联合栓塞再出血率低于单用TIPS;小肠、直肠和造口静脉曲张出血的全因死亡率分别为25.0%、42.9%和66.6%。
要点
- 直肠静脉曲张出血:内镜硬化剂注射再出血率低于套扎(3.3% vs. 33.3%)
- 各亚型中TIPS联合栓塞再出血率低于单用TIPS
- 小肠、直肠、造口静脉曲张出血全因死亡率分别为25.0%、42.9%、66.6%
核心结论
- 异位静脉曲张出血易复发且死亡率高,需个体化治疗并早期多学科讨论。
研究设计与样本
- 系统综述与汇总分析,检索Embase、MEDLINE和Cochrane Library数据库。
- 纳入44项研究(15项非连续病例系列、25项单臂回顾性队列、3项双臂回顾性队列、1项单臂前瞻性研究),共458例患者。
主要发现
- 最常见病因:酒精相关肝病38.7%、病毒性肝炎18.8%、原发性硬化性胆管炎15.7%。
- Child-Pugh A、B、C级分别占29.7%、46.7%、23.5%;汇总中位MELD评分为14.0(IQR 10.0-20.8)。
- 最常见出血部位:十二指肠27.7%、直肠27.3%、造口/造口周围23.1%。
- 直肠静脉曲张出血:内镜硬化剂注射再出血率3.3%,套扎为33.3%。
- 各亚型中TIPS联合栓塞再出血率低于单用TIPS;小肠、直肠、造口静脉曲张出血全因死亡率分别为25.0%、42.9%、66.6%,中位随访354天(IQR 120-780)。
关键数值与推荐
- 直肠静脉曲张出血:内镜硬化剂注射再出血率3.3%,套扎33.3%。
- TIPS联合栓塞再出血率低于单用TIPS(各静脉曲张亚型)。
- 小肠、直肠、造口静脉曲张出血全因死亡率分别为25.0%、42.9%、66.6%。
临床怎么用
- 直肠静脉曲张出血可优先考虑内镜硬化剂注射而非套扎。
- 考虑TIPS时联合静脉曲张栓塞可能降低再出血风险。
- 异位静脉曲张出血患者应早期启动多学科团队讨论并制定个体化方案。
局限性
- 样本量小、数据缺失及研究间显著异质性限制数据质量。
- 因研究异质性未进行传统荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding ectopic varices is a rare but life-threatening complication in patients with clinically significant portal hypertension and liver cirrhosis, with limited evidence available to guide treatment decisions. AIM: To evaluate the safety and efficacy of current therapies for bleeding ectopic varices. METHODS: A systematic review with pooled analysis was performed based on searches conducted in Embase, MEDLINE and Cochrane Library databases. Case series, retrospective and prospective studies including adults with a history of liver cirrhosis or portal hypertension presenting with bleeding ectopic varices were included. Individual patient data on interventions, rebleeding, complications and mortality were pooled and summarised using descriptive analysis. No conventional meta-analysis was conducted due to the heterogeneous nature of included studies. RESULTS: 44 studies (15 non-consecutive case series, 25 single-arm retrospective cohort studies, 3 double-arm retrospective cohort studies and 1 single-arm prospective study) involving 458 patients met selection criteria. Alcohol-related liver disease (38.7%), viral hepatitis (18.8%) and primary sclerosing cholangitis (15.7%) were the most common aetiologies. Child-Pugh A, B and C cirrhosis accounted for 29.7%, 46.7% and 23.5% of patients, respectively, and the pooled median Model for End Stage Liver Disease score was 14.0 (IQR 10.0-20.8). The most reported sites of ectopic varices were duodenal (27.7%), rectal (27.3%) and stomal/peri-stomal (23.1%). Endoscopic sclerosant injection appeared to have a lower rebleeding rate than band ligation in the treatment of bleeding rectal varices (3.3% vs. 33.3%). Across variceal subtypes, transjugular intrahepatic portosystemic shunt (TIPS) combined with variceal embolisation, was observed to have a lower rebleeding rate than TIPS alone. The pooled all-cause mortality following small bowel, rectal and stomal variceal bleeding were 25.0%, 42.9%, and 66.6%, respectively, over a median follow-up period of 354 (IQR 120-780) days. Small sample sizes, missing data and significant heterogeneity between studies limited data quality. CONCLUSION: Bleeding ectopic varices frequently recurs and carries high mortality. An individualised approach in conjunction with early multidisciplinary team discussions is essential in achieving favourable patient outcomes.
引用
- Zhu, Rasaratnam, Majeed, et al. Management and Outcomes of Bleeding Ectopic Varices in Patients With Liver Cirrhosis: A Systematic Review and Pooled Analysis. Aliment Pharmacol Ther. 2026. PMID: 42946657. doi:10.1111/apt.71072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。